商品詳細

This book provides a comprehensive overview of pathophysiological mechanisms and therapeutic frontiers of metabolic and associated disorders. Significant research efforts focus on understanding the key pathways related to metabolism and their role as therapeutic targets to control it and the associated diseases which may be chronic, debilitating and lethal. For the management of diabetes/dyslipidemia/metabolic syndrome/etc. the therapeutic interventions target improving insulin sensitivity, restoration of metabolic homeostasis, reduce cardiovascular and hepatic risks.

The book chapters present a foundational overview of metabolic dysfunction, systematically elucidating the co-morbid associations between systemic metabolic failure and cardiovascular and neurodegenerative complications. The text discusses key regulatory pathways and critical molecular targets of metabolic diseases, including brain-derived neurotrophic factor (BDNF), receptor for advanced glycation endproducts (RAGE), dipeptidyl peptidase-4 (DPP-4), pancreatic and deuodenal homeobox 1 (PDX1), proprotein convertase subtilisin/kexin type 9 (PCSK9), and galectin-3, emphasizing their role in the disease progression and their significance in the development of therapeutic interventions.

The book further addresses chromenone scaffolds, natural product–derived compounds mainly PPAR modulators, and recent advances in synthetic chemistry for anti-obesity drug development. Protective role of antioxidants in reduction of hyperglycemia-induced oxidative stress helps to lower the risk of vascular complications is provided. Dedicated chapters on diabetes associated complications like diabetic foot ulcer which is a serious complication with neuropathy and/or peripheral artery disease discusses its management. Some chapters also focus on the interconnection between diabetes and obesity, and strategies to improve disease control and therapeutic access along with lifestyle modification which is the primary foundation. The concluding sections focus on precision medicine, artificial intelligence-mediated drug discovery, in silico drug design, and future treatment directions.

Key Points

• Explores fundamental molecular pathways and the mechanical basis of diabetes, dementia, and cardiovascular complications.
• Examines targeted therapeutic regulators including PDX1, PCSK9, DPP-4, and the role of galectin-3 in metabolic dysfunction.
• Analyzes diverse pharmacological approaches, from synthetic anti-obesity drugs and chromenone scaffolds to natural PPAR modulators.
• Highlights clinical advancements in the management of diabetic foot ulcers and the systemic interconnection between obesity and diabetes.
• Explores precision medicine, in silico drug design, and AI-mediated therapeutic development for next-generation metabolic treatments.